XtalPi Filed Investigational New Drug Application for KQTD-126
The company has submitted its first proprietary drug candidate to the FDA for the treatment of chronic intestinal pain.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Do you believe using AI in drug discovery will lead to better treatments for chronic pain?
XtalPi has officially submitted an Investigational New Drug application for KQTD-126 to the U.S. Food and Drug Administration. This candidate is a gut-restricted pan-TRK inhibitor designed to alleviate chronic abdominal pain in patients with IBS and IBD.
Why it matters
The development addresses the high risk of neurological side effects associated with systemic TRK inhibitors by focusing on a gut-restricted alternative. Chronic intestinal pain remains a significant unmet clinical need for millions suffering from bowel disorders.
KQTD-126 demonstrates sub-nanomolar potency in preclinical testing. The drug was designed using a platform that integrates generative AI models with a fleet of automated chemistry robots to conduct synthesis and screening.
The players
XtalPi
This AI and robotics-driven drug discovery company operates offices in Boston and Shenzhen, China.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.
The details
The drug discovery process involved computational design, automated synthesis, empirical screening, and molecular refinement to create the novel inhibitor. XtalPi aims to improve patient outcomes by bypassing the systemic issues common to traditional TRK treatments.
Timeline
September 25, 2026: XtalPi submitted the IND application to the FDA.
2030: The global IBS and IBD therapeutics market is projected to reach US$52.6 billion.
The Tech Race
This move highlights the shift toward using AI-driven platforms to expedite the traditionally slow and costly drug discovery process. It positions XtalPi as a direct competitor to traditional pharmaceutical research firms that rely on manual discovery workflows.
Patients with IBS or IBD may eventually see a new treatment option that offers pain relief without the neurological side effects of current inhibitors. The shift toward AI-designed drugs could potentially shorten the time it takes for new therapeutic solutions to reach the market.
The takeaway
The use of generative AI in pharmacology represents a major evolution in how we target complex chronic diseases. As these AI-designed candidates advance, the industry may see a surge in specialized treatments that mitigate the adverse side effects of systemic medications.
Further reading
For more information on innovations in medical research, visit our Biotech section.
Live Poll
Do you believe using AI in drug discovery will lead to better treatments for chronic pain?
